IntAct European Bioinformatics Institute IntAct intact http://www.ebi.ac.uk/ http://www.ebi.ac.uk/intact/query/${ac} EBI-[0-9]+|IA:[0-9]+ INTerAction database (IntAct) provides an open source database and toolkit for the storage, presentation and analysis of molecular interactions. http://www.ebi.ac.uk/intact European Bioinformatics Institute; Wellcome Trust Genome Campus; Hinxton, Cambridge; CB10 1SD; United Kingdom http://www.ebi.ac.uk/intact/ Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor. Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor. Cancer Cell (1535-6108) 2010 imex curation Andersen RJ., Mawji NR., Wang J., Wang G., Haile S., Myung JK., Watt K., Tam T., Yang YC., Banuelos CA., Williams DE., McEwan IJ., Wang Y., Sadar MD. Cancer - Interactions investigated in the context of cancer msadar@bcgsc.ca 13-Sept-2010: Contacted by JYOTI. Only protein-protein interactions human-lncap Human caucasian prostate carcinoma lncap Human caucasian prostate adenocarcinoma anti bait coip anti bait coimmunoprecipitation anti bait coip western blot western blot Immuno blot Immuno blot Andersen RJ., Mawji NR., Wang J., Wang G., Haile S., Myung JK., Watt K., Tam T., Yang YC., Banuelos CA., Williams DE., McEwan IJ., Wang Y., Sadar MD. Cancer - Interactions investigated in the context of cancer msadar@bcgsc.ca Accepted 2010-JUL-21 by ORCHARD. 13-Sept-2010: Contacted by JYOTI. Cancer Cell (1535-6108) 2010 Only protein-protein interactions imex curation Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor. Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor. Cancer Cell (1535-6108) 2010 imex curation Andersen RJ., Mawji NR., Wang J., Wang G., Haile S., Myung JK., Watt K., Tam T., Yang YC., Banuelos CA., Williams DE., McEwan IJ., Wang Y., Sadar MD. Cancer - Interactions investigated in the context of cancer msadar@bcgsc.ca 13-Sept-2010: Contacted by JYOTI. Only protein-protein interactions in vitro In vitro fps fluorescence polarization spectroscopy Fluorescence anisotropy FPS FPS Fluorescence anisotropy fps tag fluorescence tag visualisation by fluorescence tag fluorescence Andersen RJ., Mawji NR., Wang J., Wang G., Haile S., Myung JK., Watt K., Tam T., Yang YC., Banuelos CA., Williams DE., McEwan IJ., Wang Y., Sadar MD. Cancer - Interactions investigated in the context of cancer Fluorescent polarization. AR-LBD(His-GST)(Rat Androgen-Receptor Ligand-Binding Domain)is added to a fluorescently-tagged androgen ligand (Fluormone�) in the presence of competitor test compounds in microwell plates. The presence of effective competitors prevents the formation of a Fluormone/ AR-LBD(His-GST) complex resulting in a decrease of the polarization value due to ligand displacement caused by a competitor. Details of androgen receptor construct taken from manufacturer's website. msadar@bcgsc.ca Accepted 2010-JUL-21 by ORCHARD. 13-Sept-2010: Contacted by JYOTI. Cancer Cell (1535-6108) 2010 Only protein-protein interactions imex curation Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor. Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor. Cancer Cell (1535-6108) 2010 imex curation Andersen RJ., Mawji NR., Wang J., Wang G., Haile S., Myung JK., Watt K., Tam T., Yang YC., Banuelos CA., Williams DE., McEwan IJ., Wang Y., Sadar MD. Cancer - Interactions investigated in the context of cancer msadar@bcgsc.ca 13-Sept-2010: Contacted by JYOTI. Only protein-protein interactions in vitro In vitro pull down pull down tag visualisation tag visualisation Andersen RJ., Mawji NR., Wang J., Wang G., Haile S., Myung JK., Watt K., Tam T., Yang YC., Banuelos CA., Williams DE., McEwan IJ., Wang Y., Sadar MD. Cancer - Interactions investigated in the context of cancer msadar@bcgsc.ca Accepted 2010-JUL-21 by ORCHARD. 13-Sept-2010: Contacted by JYOTI. Cancer Cell (1535-6108) 2010 Only protein-protein interactions imex curation Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor. Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor. Cancer Cell (1535-6108) 2010 imex curation Andersen RJ., Mawji NR., Wang J., Wang G., Haile S., Myung JK., Watt K., Tam T., Yang YC., Banuelos CA., Williams DE., McEwan IJ., Wang Y., Sadar MD. Cancer - Interactions investigated in the context of cancer msadar@bcgsc.ca 13-Sept-2010: Contacted by JYOTI. Only protein-protein interactions human-lncap Human caucasian prostate carcinoma lncap Human caucasian prostate adenocarcinoma ch-ip chromatin immunoprecipitation assay ch-ip primer specific pcr primer specific pcr Andersen RJ., Mawji NR., Wang J., Wang G., Haile S., Myung JK., Watt K., Tam T., Yang YC., Banuelos CA., Williams DE., McEwan IJ., Wang Y., Sadar MD. Cancer - Interactions investigated in the context of cancer msadar@bcgsc.ca Accepted 2010-JUL-21 by ORCHARD. Cancer Cell (1535-6108) 2010 Only protein-protein interactions imex curation klk3_human_gene Human kallikrein-related peptidase 3 (KLK3) (PSA) gene gene human Homo sapiens Human andr_rat Androgen receptor Ar Nr3c4 Dihydrotestosterone receptor Nuclear receptor subfamily 3 group C member 4 protein protein rat Rattus norvegicus (Rat) Rat MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREAIQNPGPRHPEAASIAPPGACLQQRQETSPRRRRRQQHPEDGSPQAHIRGTTGYLALEEEQQPSQQQSASEGHPESGCLPEPGAATAPGKGLPQQPPAPPDQDDSAAPSTLSLLGPTFPGLSSCSADIKDILSEAGTMQLLQQQQQQQQQQQQQQQQQQQQQQEVISEGSSSVRAREATGAPSSSKDSYLGGNSTISDSAKELCKAVSVSMGLGVEALEHLSPGEQLRGDCMYASLLGGPPAVRPTPCAPLAECKGLSLDEGPGKGTEETAEYSSFKGGYAKGLEGESLGCSGSSEAGSSGTLEIPSSLSLYKSGAVDEAAAYQNRDYYNFPLALSGPPHPPPPTHPHARIKLENPSDYGSAWAAAAAQCRYGDLASLHGGSVAGPSTGSPPATASSSWHTLFTAEEGQLYGPGGGGGSSSPSDAGPVAPYGYTRPPQGLASQEGDFSASEVWYPGGVVNRVPYPSPSCVKSEMGPWMENYSGPYGDMRLDSTRDHVLPIDYYFPPQKTCLICGDEASGCHYGALTCGSCKVFFKRAAEGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGARKLKKLGNLKLQEEGENSSAGSPTEDPSQKMTVSHIEGYECQPIFLNVLEAIEPGVVCAGHDNNQPDSFAALLSSLNELGERQLVHVVKWAKALPGFRNLHVDDQMAVIQYSWMGLMVFAMGWRSFTNVNSRMLYFAPDLVFNEYRMHKSRMYSQCVRMRHLSQEFGWLQITPQEFLCMKALLLFSIIPVDGLKNQKFFDELRMNYIKELDRIIACKRKNPTSCSRRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEMMAEIISVQVPKILSGKVKPIYFHTQ 43F4064759FDCBED t2fa_human General transcription factor IIF subunit 1 Transcription initiation factor IIF subunit alpha GTF2F1 RAP74 Transcription initiation factor RAP74 General transcription factor IIF 74 kDa subunit protein protein human Homo sapiens Human MAALGPSSQNVTEYVVRVPKNTTKKYNIMAFNAADKVNFATWNQARLERDLSNKKIYQEEEMPESGAGSEFNRKLREEARRKKYGIVLKEFRPEDQPWLLRVNGKSGRKFKGIKKGGVTENTSYYIFTQCPDGAFEAFPVHNWYNFTPLARHRTLTAEEAEEEWERRNKVLNHFSIMQQRRLKDQDQDEDEEEKEKRGRRKASELRIHDLEDDLEMSSDASDASGEEGGRVPKAKKKAPLAKGGRKKKKKKGSDDEAFEDSDDGDFEGQEVDYMSDGSSSSQEEPESKAKAPQQEEGPKGVDEQSDSSEESEEEKPPEEDKEEEEEKKAPTPQEKKRRKDSSEESDSSEESDIDSEASSALFMAKKKTPPKRERKPSGGSSRGNSRPGTPSAEGGSTSSTLRAAASKLEQGKRVSEMPAAKRLRLDTGPQSLSGKSTPQPPSGKTTPNSGDVQVTEDAVRRYLTRKPMTTKDLLKKFQTKKTGLSSEQTVNVLAQILKRLNPERKMINDKMHFSLKE DIP protein P35269 original sequence version: 109 DIP protein P35269 original sequence version: 171 DIP protein P35269 original sequence version: 164 1032B04A36BDC24F tmps2_human_gene Human TMPS2/TMPRSS2 gene gene gene human Homo sapiens Human r1881 R1881, Metribolone, a synthetic androgen small molecule small molecule chemical synthesis Chemical synthesis (Chemical synthesis) Also known as methyltrienolone. (17-methyloestra-4,9,11-trien-3-one,17b-ol). Also known as methyltrienolone. (17-methyloestra-4,9,11-trien-3-one,17b-ol). cbp_human CREB-binding protein CREBBP CBP Histone lysine acetyltransferase CREBBP Protein-lysine acetyltransferase CREBBP protein protein human Homo sapiens Human MAENLLDGPPNPKRAKLSSPGFSANDSTDFGSLFDLENDLPDELIPNGGELGLLNSGNLVPDAASKHKQLSELLRGGSGSSINPGIGNVSASSPVQQGLGGQAQGQPNSANMASLSAMGKSPLSQGDSSAPSLPKQAASTSGPTPAASQALNPQAQKQVGLATSSPATSQTGPGICMNANFNQTHPGLLNSNSGHSLINQASQGQAQVMNGSLGAAGRGRGAGMPYPTPAMQGASSSVLAETLTQVSPQMTGHAGLNTAQAGGMAKMGITGNTSPFGQPFSQAGGQPMGATGVNPQLASKQSMVNSLPTFPTDIKNTSVTNVPNMSQMQTSVGIVPTQAIATGPTADPEKRKLIQQQLVLLLHAHKCQRREQANGEVRACSLPHCRTMKNVLNHMTHCQAGKACQVAHCASSRQIISHWKNCTRHDCPVCLPLKNASDKRNQQTILGSPASGIQNTIGSVGTGQQNATSLSNPNPIDPSSMQRAYAALGLPYMNQPQTQLQPQVPGQQPAQPQTHQQMRTLNPLGNNPMNIPAGGITTDQQPPNLISESALPTSLGATNPLMNDGSNSGNIGTLSTIPTAAPPSSTGVRKGWHEHVTQDLRSHLVHKLVQAIFPTPDPAALKDRRMENLVAYAKKVEGDMYESANSRDEYYHLLAEKIYKIQKELEEKRRSRLHKQGILGNQPALPAPGAQPPVIPQAQPVRPPNGPLSLPVNRMQVSQGMNSFNPMSLGNVQLPQAPMGPRAASPMNHSVQMNSMGSVPGMAISPSRMPQPPNMMGAHTNNMMAQAPAQSQFLPQNQFPSSSGAMSVGMGQPPAQTGVSQGQVPGAALPNPLNMLGPQASQLPCPPVTQSPLHPTPPPASTAAGMPSLQHTTPPGMTPPQPAAPTQPSTPVSSSGQTPTPTPGSVPSATQTQSTPTVQAAAQAQVTPQPQTPVQPPSVATPQSSQQQPTPVHAQPPGTPLSQAAASIDNRVPTPSSVASAETNSQQPGPDVPVLEMKTETQAEDTEPDPGESKGEPRSEMMEEDLQGASQVKEETDIAEQKSEPMEVDEKKPEVKVEVKEEEESSSNGTASQSTSPSQPRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLGYCCGRKYEFSPQTLCCYGKQLCTIPRDAAYYSYQNRYHFCEKCFTEIQGENVTLGDDPSQPQTTISKDQFEKKKNDTLDPEPFVDCKECGRKMHQICVLHYDIIWPSGFVCDNCLKKTGRPRKENKFSAKRLQTTRLGNHLEDRVNKFLRRQNHPEAGEVFVRVVASSDKTVEVKPGMKSRFVDSGEMSESFPYRTKALFAFEEIDGVDVCFFGMHVQEYGSDCPPPNTRRVYISYLDSIHFFRPRCLRTAVYHEILIGYLEYVKKLGYVTGHIWACPPSEGDDYIFHCHPPDQKIPKPKRLQEWYKKMLDKAFAERIIHDYKDIFKQATEDRLTSAKELPYFEGDFWPNVLEESIKELEQEEEERKKEESTAASETTEGSQGDSKNAKKKNNKKTNKNKSSISRANKKKPSMPNVSNDLSQKLYATMEKHKEVFFVIHLHAGPVINTLPPIVDPDPLLSCDLMDGRDAFLTLARDKHWEFSSLRRSKWSTLCMLVELHTQGQDRFVYTCNECKHHVETRWHCTVCEDYDLCINCYNTKSHAHKMVKWGLGLDDEGSSQGEPQSKSPQESRRLSIQRCIQSLVHACQCRNANCSLPSCQKMKRVVQHTKGCKRKTNGGCPVCKQLIALCCYHAKHCQENKCPVPFCLNIKHKLRQQQIQHRLQQAQLMRRRMATMNTRNVPQQSLPSPTSAPPGTPTQQPSTPQTPQPPAQPQPSPVSMSPAGFPSVARTQPPTTVSTGKPTSQVPAPPPPAQPPPAAVEAARQIEREAQQQQHLYRVNINNSMPPGRTGMGTPGSQMAPVSLNVPRPNQVSGPVMPSMPPGQWQQAPLPQQQPMPGLPRPVISMQAQAAVAGPRMPSVQPPRSISPSALQDLLRTLKSPSSPQQQQQVLNILKSNPQLMAAFIKQRTAKYVANQPGMQPQPGLQSQPGMQPQPGMHQQPSLQNLNAMQAGVPRPGVPPQQQAMGGLNPQGQALNIMNPGHNPNMASMNPQYREMLRRQLLQQQQQQQQQQQQQQQQQQGSAGMAGGMAGHGQFQQPQGPGGYPPAMQQQQRMQQHLPLQGSSMGQMAAQMGQLGQMGQPGLGADSTPNIQQALQQRILQQQQMKQQIGSPGQPNPMSPQQHMLSGQPQASHLPGQQIATSLSNQVRSPAPVQSPRPQSQPPHSSPSPRIQPQPSPHHVSPQTGSPHPGLAVTMASSIDQGHLGNPEQSAMLPQLNTPSRSALSSELSLVGDTTGDTLEKFVEGL DIP protein Q92793 original sequence version: 134 DIP protein Q92793-1 original sequence version: 171 DIP protein Q92793 original sequence version: 171 DIP protein Q92793 original sequence version: 185 DIP protein Q92793 original sequence version: 106 DIP protein Q92793 original sequence version: 104 DIP protein Q92793 original sequence version: 112 DIP protein Q92793 original sequence version: 135 DIP protein Q92793 original sequence version: 139 DIP protein Q92793 original sequence version: 157 DIP protein Q92793 original sequence version: 177 DIP protein Q92793 original sequence version: 168 DIP protein Q92793-1 original sequence version: 174 DIP protein Q92793 original sequence version: 146 DIP protein Q92793 original sequence version: 161 DIP protein Q92793 original sequence version: 172 3BEA9B8558BA1A5E fluormone_al_green Fluormone� AL Green, an androgen ligand, a fluorescent androgen analog. small molecule small molecule chemical synthesis Chemical synthesis (Chemical synthesis) a fluorescently-tagged androgen ligand (Fluormone� AL Green)- supplied by Invitrogen. It binds AR-LBD with a similar affinity as DHT. a fluorescently-tagged androgen ligand (Fluormone� AL Green)- supplied by Invitrogen. It binds AR-LBD with a similar affinity as DHT. andr_human Androgen receptor Dihydrotestosterone receptor Nuclear receptor subfamily 3 group C member 4 AR DHTR NR3C4 protein protein human Homo sapiens Human MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPPGASLLLLQQQQQQQQQQQQQQQQQQQQQQQETSPRQQQQQQGEDGSPQAHRRGPTGYLVLDEEQQPSQPQSALECHPERGCVPEPGAAVAASKGLPQQLPAPPDEDDSAAPSTLSLLGPTFPGLSSCSADLKDILSEASTMQLLQQQQQEAVSEGSSSGRAREASGAPTSSKDNYLGGTSTISDNAKELCKAVSVSMGLGVEALEHLSPGEQLRGDCMYAPLLGVPPAVRPTPCAPLAECKGSLLDDSAGKSTEDTAEYSPFKGGYTKGLEGESLGCSGSAAAGSSGTLELPSTLSLYKSGALDEAAAYQSRDYYNFPLALAGPPPPPPPPHPHARIKLENPLDYGSAWAAAAAQCRYGDLASLHGAGAAGPGSGSPSAAASSSWHTLFTAEEGQLYGPCGGGGGGGGGGGGGGGGGGGGGGGEAGAVAPYGYTRPPQGLAGQESDFTAPDVWYPGGMVSRVPYPSPTCVKSEMGPWMDSYSGPYGDMRLETARDHVLPIDYYFPPQKTCLICGDEASGCHYGALTCGSCKVFFKRAAEGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGARKLKKLGNLKLQEEGEASSTTSPTEETTQKLTVSHIEGYECQPIFLNVLEAIEPGVVCAGHDNNQPDSFAALLSSLNELGERQLVHVVKWAKALPGFRNLHVDDQMAVIQYSWMGLMVFAMGWRSFTNVNSRMLYFAPDLVFNEYRMHKSRMYSQCVRMRHLSQEFGWLQITPQEFLCMKALLLFSIIPVDGLKNQKFFDELRMNYIKELDRIIACKRKNPTSCSRRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEMMAEIISVQVPKILSGKVKPIYFHTQ DIP protein P10275 original sequence version: 220 DIP protein P10275-1 original sequence version: 213 DIP protein P10275 original sequence version: 216 DIP protein P10275 original sequence version: 143 DIP protein P10275 original sequence version: 174 DIP protein P10275 original sequence version: 169 DIP protein P10275 original sequence version: 188 DIP protein P10275-1 original sequence version: 188 DIP protein P10275 original sequence version: 196 DIP protein P10275 original sequence version: 217 DIP protein P10275-1 original sequence version: 217 DIP protein P10275-1 original sequence version: 207 A73432C55D39AE06 bicalutamide Bicalutamide, an androgen antagonist small molecule small molecule chemical synthesis Chemical synthesis (Chemical synthesis) klk3-andr 4 5 unspecified role unspecified role prey prey 12 unspecified role unspecified role bait bait association association R1881, a synthetic androgen. EPI-001:a small molecule derived from marine sponge extracts, that inhibits transactivation of the AR amino-terminal domain. R1881 treatment significantly increased AR and CBP binding to AREs in promoter and enhancer of PSA and TMPRSS2-ARE, which was significantly inhibited by EPI-001. Figure 2C. klk3-cbp 4 5 unspecified role unspecified role prey prey 10 unspecified role unspecified role bait bait association association R1881, a synthetic androgen. EPI-001:a small molecule derived from marine sponge extracts, that inhibits transactivation of the AR amino-terminal domain. R1881 treatment significantly increased AR and CBP binding to AREs in promoter and enhancer of PSA and TMPRSS2-ARE, which was significantly inhibited by EPI-001. Figure 2C. tmps2-cbp 4 10 unspecified role unspecified role bait bait 8 unspecified role unspecified role prey prey association association R1881, a synthetic androgen. EPI-001:a small molecule derived from marine sponge extracts, that inhibits transactivation of the AR amino-terminal domain. R1881 treatment significantly increased AR and CBP binding to AREs in promoter and enhancer of PSA and TMPRSS2-ARE, which was significantly inhibited by EPI-001. Figure 2D. tmps2-andr 4 8 unspecified role unspecified role prey prey 12 unspecified role unspecified role bait bait association association R1881, a synthetic androgen. EPI-001:a small molecule derived from marine sponge extracts, that inhibits transactivation of the AR amino-terminal domain. R1881 treatment significantly increased AR and CBP binding to AREs in promoter and enhancer of PSA and TMPRSS2-ARE, which was significantly inhibited by EPI-001. Figure 2D. ar-cbp 1 10 unspecified role unspecified role bait bait 12 unspecified role unspecified role prey prey physical association physical association R1881, a synthetic androgen. EPI-001:a small molecule derived from marine sponge extracts, that inhibits transactivation of the AR amino-terminal domain. EPI-001 prevents physical interaction between endogenous AR and CBP. Figure 3E. IL-6 ar-cbp-1 3 12 unspecified role unspecified role bait bait af1_domain sufficient to bind sufficient binding region sufficient to bind range range range range 10 unspecified role unspecified role prey prey n terminal domain sufficient to bind sufficient binding region sufficient to bind undetermined undetermined sequence position undetermined undetermined undetermined sequence position undetermined physical association physical association EPI-001:a small molecule derived from marine sponge extracts, that inhibits transactivation of the AR amino-terminal domain. EPI-001 inhibited interaction between AF-1 (AR NTD) and CBP-CTD recombinant proteins as well as AF-1 interaction with the large subunit of general transcription factor TFIIF (RAP74). Figure 3F. aa numbers for the domain were not given in the paper or UniProt - found in the literature. 185-9-1 not entered as it is an "inactive" control. ar-t2fa 3 7 unspecified role unspecified role prey prey c terminal domain sufficient to bind sufficient binding region sufficient to bind c-term range C-terminal range c-term range c-term range C-terminal range c-term range 12 unspecified role unspecified role bait bait af1_domain sufficient to bind sufficient binding region sufficient to bind range range range range physical association physical association EPI-001:a small molecule derived from marine sponge extracts, that inhibits transactivation of the AR amino-terminal domain. EPI-001 inhibited interaction between AF-1 (AR NTD) and CBP-CTD recombinant proteins as well as AF-1 interaction with the large subunit of general transcription factor TFIIF (RAP74). Figure 3F. aa numbers for the AF1 domain were not given in the paper or UniProt -so found in the literature. 185-9-1 not entered as it is an "inactive" control. andr-fluormone_bic 2 11 competitor competitor competitor prey prey 6 unspecified role unspecified role bait bait lbd domain sufficient to bind sufficient binding region sufficient to bind range range range range region gst tag glutathione s tranferase tag glutathione S-tranferase tag glutathione S-tranferase tag gst tag undetermined undetermined sequence position undetermined undetermined undetermined sequence position undetermined region his tag his tag Hexa-His-tag 6-His-tag Histidine-tag Hexa-His-tag Histidine-tag 6-His-tag undetermined undetermined sequence position undetermined undetermined undetermined sequence position undetermined 13 unspecified role unspecified role prey prey physical association physical association Fig 3B. Both R1881 and bicalutamide bound to the AR-LBD as expected. EPI-001 in the concentration range of 0.1 nM to 100 uM did not prevent ligand-binding. andr-fluormone_r1881 2 9 unspecified role unspecified role prey prey 11 competitor competitor competitor prey prey 6 unspecified role unspecified role bait bait lbd domain sufficient to bind sufficient binding region sufficient to bind range range range range region gst tag glutathione s tranferase tag glutathione S-tranferase tag glutathione S-tranferase tag gst tag undetermined undetermined sequence position undetermined undetermined undetermined sequence position undetermined region his tag his tag Hexa-His-tag 6-His-tag Histidine-tag Hexa-His-tag Histidine-tag 6-His-tag undetermined undetermined sequence position undetermined undetermined undetermined sequence position undetermined physical association physical association Fig 3B. Both R1881 and bicalutamide bound to the AR-LBD as expected. EPI-001 in the concentration range of 0.1 nM to 100 uM did not prevent ligand-binding.